AI Summary & Key Takeaways
AI InsightThere were four recurrent cases.The five-year disease-freesurvival (DFS) rate and overall survival (OS) rate was 50% and 66.7%, respectively.
📌 3 Key Takeaways
Abstract
Aim:The objective of this study was to analyzestage IIIB endometrioid type endometrial cancer. Material and Methods:This study was conducted in two gynecologic oncology centers between January 2007 and December 2016. Endometrial cancer was staged according to the International Federation of Gynecology and Obstetrics (FIGO) staging system and stage IIIB endometrioid type endometrial cancer patients were included in the study.The clinicopathologic findings of the patients were analyzed by reaching through the hospital database. Result: A total of 1700 endometrial cancer patients were investigated and of these patients, 10 were diagnosed with stage IIIB endometrioid type endometrial cancer. The median age of the patients were 62 years (49-85) and the median follow-upwas 45 months (20-93). Four and four patients were diagnosed with vaginal involvement andparametrial involvement, respectively. Two patients were diagnosed withboth vaginal and parametrial involvement. Six (60%) patients underwent radical hysterectomy and 4 (40%) patients underwent simple hysterectomy. Six patients received adjuvan chemotherapy. Only one patient received adjuvan pelvic radiotherapy whereas 3 patients received adjuvan vaginal brakitherapydue to advanced age. There were four recurrent cases.The five-year disease-freesurvival (DFS) rate and overall survival (OS) rate was 50% and 66.7%, respectively. Conclusion: Stage IIIB endometroid type endometrium cancer represents a rare specific subgroup of endometroid type endometrium cancer. As our knowledge this is the only study in the national literature. There is need for multi-center studies involving large number of patients.
Özet
Giriş: Bu çalışmanın amacı Evre IIIB endometrioid tip endometriumkanseri tanısı konulan olguları analiz etmektir.Gereç ve Yöntemler: Bu çalışma Ocak 2007-Aralık 2016 yılları arasındaUluslararası Obstetri ve Jinekoloji Federasyonu (FIGO) kriterlerine göreevre IIIB tanısı konulan hastaların dahil edildiği retrospektif iki merkezli birçalışmadır. Olguların klinikopatolojik özellikleri kaydedilerek analiz edildi.Bulgular: Toplam 1700 endometrioid tip endometrium incelenmiş olupevre IIIB tanısı konulan 10 (% 0,6) hasta tespit edildi. Olguların ortancayaşı 62 (49-85), ortanca takip süresi ise 45 (20-93) ay tespit edildi.Dört olguda vajinal, 4 olguda parametrium ve 2 olguda ise hem vajinalhem parametrial tutulum izlendi. Altı (%60) olguya radikal histerektomi, 4(%40) olguya basit histerektomi yapıldı. Altı olguya adjuvan tedavi olarakkemoradyoterapi, 1 olguya sadece pelvik radyoterapi, yaşı ileri olan 3olguya ise sadece vajinal brakiterapi verildi. Dört olguda nüks meydanageldi. Olguların 5 yıllık hastalıksız sağkalım (DFS)ve genel sağkalım(OS)oranı sıra ile %50 ve %66,7 olarak bulundu.Sonuç: Evre IIIB endometrioid tip endometrium kanseri nadir bir spesifikalt grubu temsil etmektedir. Bu çalışma ulusal literatürdeki tek çalışmadır.Daha geniş serili ve çok merkezli çalışmalara ihtiyaç vardır.